Blood Screening Market Demand Analysis

1. Blood Opportunity 2037 Screening Market Demand Analysis & The Blood Screening Market is valued at USD 5.9 billion in 2025 and is projected to reach USD 15 billion by the end of 2038, expanding at a CAGR of 6.9% during the forecast period. This substantial growth is attributed to the rising burden of infectious diseases, the global push for safer blood transfusions, and increasing government regulations and screening mandates across healthcare systems. Blood Screening Industry Demand The Blood Screening Market comprises diagnostic procedures and tools used to test donated blood for the presence of infectious agents or other potentially harmful substances. The primary aim is to prevent transfusion-transmitted infections (TTIs) and ensure the safety of both recipients and donors. Demand in this market is surging due to a range of healthcare and technological advancements: •Cost-effectiveness: Blood screening solutions, especially automated ones, help reduce labor costs and minimize human error, making them a preferred choice for high-throughput laboratories. •Ease of administration: Rapid tests and automated platforms streamline workflows and reduce the need for manual intervention, making them suitable for public health programs and blood banks. •Long shelf life of reagents and kits: Stable and standardized kits ensure accurate results over extended periods, improving efficiency in inventory and resource management. Furthermore, increased awareness of blood-borne diseases, rising surgical procedures, and greater reliance on blood banks are driving adoption global Request Report Sample@ https://www.researchnester.com/sample-request- 4480 Blood Screening Market: Growth Drivers & Key Restraint Growth Drivers – 1.Rising Prevalence of Infectious and Chronic Diseases An increasing incidence of hepatitis, HIV, syphilis, malaria, and other blood- transmissible infections has led to stricter screening protocols globally. Blood

2. screening is also becoming integral in managing chronic disease cases, especially for patients undergoing surgeries or transfusions. 2.Technological Advancements in Screening Techniques The introduction of next-generation diagnostics such as Nucleic Acid Testing (NAT), ELISA, and multiplex testing platforms has significantly enhanced test sensitivity and turnaround times, enabling early detection and prevention. 3.Outsourcing and Centralized Screening Services Many healthcare providers and governments are outsourcing blood testing to specialized labs with automated systems, ensuring consistency, scalability, and cost-effectiveness. This shift is fueling demand for high-performance reagents, instruments, and data management software. Key Restraint: •High Cost of Advanced Testing Systems While advanced testing technologies offer improved accuracy and speed, the initial setup and maintenance cost for equipment like NAT-based systems and automated ELISA platforms remains high—especially in low- and middle- income countries. This cost barrier limits full market penetration in resource- constrained settings. Blood Screening Market: Segment Analysis Segment Analysis By Test Type:– •Automated Screening dominates the market due to its ability to handle high sample volumes with minimal manual input. It is widely adopted by large hospitals, national blood programs, and private labs where efficiency and reliability are paramount. •Manual Screening is still relevant in smaller clinics and rural healthcare settings, where budget constraints or low sample volumes make automation less feasible. However, its market share is gradually decreasing as automation becomes more accessible. Segment Analysis By Product Type:– •Reagents & Kits: These are essential for routine testing and include all components necessary to detect pathogens or markers. Their recurring demand makes them a backbone of the market. •NAT Reagents & Kits: Highly sensitive and capable of early-stage pathogen detection, these are becoming the gold standard in developed healthcare systems. •ELISA Reagents & Kits: Used widely for detecting antibodies and antigens, these kits remain critical for large-scale screening and research labs. •Other Reagents & Kits: Includes buffers, diluents, and control solutions used for maintaining test accuracy and performance. •Instruments: Includes platforms for NAT, ELISA, and rapid testing—ranging from compact analyzers to high-throughput systems.

3. •Automated Screening Systems: Fully integrated platforms used in centralized labs to handle large sample volumes with high precision. •Manual Screening Equipment: Includes basic diagnostic tools used in point- of-care or remote locations. •Software: Data management systems that streamline reporting, compliance tracking, and real-time monitoring—gaining importance in digitized healthcare ecosystems. Segment Analysis By Technology: The market comprises a wide range of technologies that serve specific testing needs: •Nucleic Acid Testing (NAT): This molecular-based method is lauded for its high sensitivity in early infection detection, especially for HIV, HCV, and HBV. NAT is the fastest-growing technology in blood screening. •ELISA (Enzyme-Linked Immunosorbent Assay): A traditional yet highly reliable method for detecting antibodies and antigens. It continues to be a preferred choice for large-scale, low-cost screening. •Rapid Tests: Offer immediate results, especially useful in emergency settings or regions with limited lab access. •Western Blot: Used as a confirmatory test, particularly in HIV diagnostics, but less favored due to complexity and cost. •Immunoassay Reagents: Includes immunosorbents, conjugates, substrates, and controls that enhance assay performance and specificity. •Labelling & Detection Reagents: Vital for ensuring visibility and interpretability in both manual and automated formats. •Buffers, Primers, Nucleotides, and Probes: Used in NAT and other molecular assays for amplification and detection, these support accurate diagnostics across various platforms. Each technology plays a role in shaping the diagnostic landscape depending on budget, disease prevalence, lab capability, and turnaround expectations. Blood Screening Market: Regional Insights North America: North America is a global leader in blood screening due to its highly advanced healthcare infrastructure, strict regulatory standards, and high rates of voluntary blood donation. The presence of key players, advanced technologies, and strong reimbursement policies further bolster market expansion. Government-backed blood safety initiatives continue to drive adoption of NAT and ELISA technologies. Europe: Europe follows closely, with strong national healthcare systems and unified screening regulations across countries. The demand is largely driven by aging populations, increasing surgical interventions, and a strong push for early detection of infectious

4. diseases. Innovation and adoption of AI-driven screening platforms are also becoming more prevalent. Asia-Pacific (APAC): APAC is witnessing the fastest growth due to large population bases, improving healthcare access, and rising awareness of safe blood practices. Countries like India and China are making substantial investments in hospital infrastructure and public health programs. Cost-effective technologies and international partnerships are accelerating screening adoption across both urban and rural areas. Top Players in the Blood Screening Market The Blood Screening Market is highly competitive and features a mix of global leaders and regional innovators. Key players include Roche, Abbott, Grifols, Bio-Rad, Thermo Fisher Scientific, Siemens Healthineers, and others. These companies are consistently investing in R&D, expanding their reagent portfolios, and upgrading instruments to meet the evolving demands of diagnostic laboratories and blood banks worldwide. Access screening-market/4480 Detailed Report@ https://www.researchnester.com/reports/blood- Contact for more Info: AJ Daniel Email: info@researchnester.com U.S. Phone: +1 646 586 9123 U.K. Phone: +44 203 608 5919